Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, immune response, and preliminary clinical efficacy of a candidate vaccine for urinary tract infections UTIs in adults aged 18 to 64 years. This trial focuses on adults generally for safety and immune response, and specifically on females with a history of at least one confirmed E. coli UTI within the past year for clinical efficacy. The study includes two parts an initial dose-escalation safety phase and a proof-of-principle efficacy phase, designed to establish the highest tolerated dose and evaluate the vaccines impact on UTI occurrence. Participants receive one of several vaccine dose formulations or placebo administered by injection on Day 1 and Day 61. Part 1 involves healthy male and female adults and tests increasing antigen doses for safety. After safety review, Part 2 enrolls females with previous E. coli UTIs to assess vaccine efficacy compared to placebo over a 12-month period. The vaccine is given intramuscularly following a 0 and 2 months schedule. Throughout the study, participants are monitored for side effects at the injection site and systemic reactions during the first week after each dose, as well as for any adverse events up to 426 days from the first dose. Blood tests, pregnancy monitoring, and clinical exams are conducted. The main outcome measures include the frequency of adverse events and the rate of urine culture confirmed UTIs in females during the follow-up period. Participants are followed closely for safety and immune response, with the trial lasting over a year from initial vaccination.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with various recurrent or metastatic solid tumors, including endometrial cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, hepatocellular carcinoma, adenocarcinoma of the esophagus and stomach, urothelial carcinoma, ovarian cancer, cervical cancer, biliary tract cancer, HER2-low and HER2 IHC 0 breast cancer, cutaneous melanoma, and neuroendocrine carcinoma. The study is an open-label, phase 1B2 trial with multiple cohorts and includes a safety run-in phase for hepatocellular carcinoma participants. Participants receive I-DXd through intravenous infusions at a dose of 12 mgkg with a determined dose for hepatocellular carcinoma in repeated cycles. The trial is divided into three parts Stage 1, Stage 2, and an optional Stage 3 for the endometrial cancer cohort based on safety and efficacy data. Each cohort starts with Stage 1 and may progress to Stage 2 if criteria are met. The hepatocellular carcinoma cohort undergoes a safety run-in phase to assess tolerability. During the trial, participants will have tumor samples collected before treatment, imaging assessments to measure disease response, and regular monitoring for side effects and adverse events. Researchers will evaluate objective response rate, dose-limiting toxicities, treatment-emergent adverse events, duration of response, progression-free survival, disease control rate, overall survival, pharmacokinetics, and immune responses over a period of up to approximately 60 months. Participants will be followed closely through scheduled visits and tests throughout the study duration.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of macupatide and eloralintide, alone or combined, in managing weight among adults who are overweight or obese but do not have type 2 diabetes. The study is conducted under a master protocol and seeks to understand how these treatments affect body weight changes over time. Participants are randomly assigned to one of several groups to receive macupatide, eloralintide, their combination, or a placebo. All treatments are given through subcutaneous injections. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The main treatment period lasts about 36 weeks, with additional assessments extending to around 64 weeks. During the study, participants will be closely monitored through various visits to assess changes in body weight and body mass index. Researchers will measure the percentage change in body weight from the start of the study to week 36 and beyond. Safety and adherence will also be tracked throughout the study, which lasts approximately 64 weeks in total.
Actively Recruiting
Researchers are evaluating a new medicine called Risvutatug Rezetecan also known as GSK5764227 in participants worldwide who have advanced gastrointestinal cancers that cannot be surgically removed. This study focuses on participants who have already received prior treatment and aims to assess how well the medicine works, how safe it is, and how the body processes it. It is a Phase 1b2, multicenter, open-label trial sponsored by GlaxoSmithKline. Participants will receive Risvutatug Rezetecan alone or in combination with other treatments. Multiple dosing groups exist, including different doses tailored to colon, rectum, and pancreatic cancer cohorts. The study uses a randomized, parallel design to compare these groups. Treatments are given according to assigned doses, and the trial monitors participants for up to approximately 37 months to assess response and safety. During the study, participants will undergo regular assessments including scans, blood tests, vital signs, and electrocardiograms. Researchers will measure confirmed objective response rates up to about 22 months, and additional outcomes such as progression-free survival, duration of response, adverse events, and changes in clinical and laboratory parameters over about 37 months. Participants are monitored closely for safety and treatment effects throughout their involvement in the trial.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type. Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options. During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.
Actively Recruiting
Researchers are conducting a global, multi-center observational trial to study patients with recurrent symptomatic paroxysmal or persistent atrial fibrillation AF. The trial evaluates the PulseSelect PFA System, a market-approved device used for pulmonary vein isolation, to better understand its safety and effectiveness over a 36-month period. This study follows patients who have not responded well to at least one Class I or III antiarrhythmic drug. Participants will undergo an ablation procedure using the PulseSelect PFA System according to standard hospital care. The study observes two groups based on AF type paroxysmal and persistent. After treatment, patients will be followed with scheduled visits at 3, 6, 12, 24, and 36 months, including 24-hour Holter heart monitoring at the 6, 12, 24, and 36 month visits. During the study, participants will have regular assessments to track heart rhythm and safety outcomes. Researchers will measure freedom from atrial fibrillation at 36 months after ablation and monitor for device- or procedure-related adverse events up to 6 months. The total participant involvement spans three years, providing long-term data on treatment outcomes and safety.
1-10 of 12
1